Table 1.
Baseline demographic and concurrent clinical manifestations in 50 patients with idiopathic and Behçet’s disease-associated posterior uveitis
| Overall | Idiopathic PU | BD-associated PU | |
|---|---|---|---|
| Patient number | 50 | 14 | 36 |
| Male/female (no/%) | 20 (40%)/30 (60%) | 5 (36%)/9 (64%) | 15 (42%)/21 (58%) |
| Age at first visit (years/mean ± SD) | 37.5 ± 12.3 | 40.9 ± 15.3 | 36.1 ± 10.9 |
| Disease duration (months/mean ± SD) | 60.3 ± 64.6 | 51.1 ± 48.4 | 63.8 ± 70.2 |
| HLA-B51+ (no/%) | 26 (52%) | 3 (21%) | 23 (64%) |
| ESR (mm/h/mean ± SD) | 29.5 ± 14.2 | 28.6 ± 13.8 | 29.8 ± 14.5 |
| CRP (mg/dL/mean ± SD) | 1.25 ± 1.1 | 0.84 ± 0.7 | 1.41 ± 1.2 |
| Bilateral PU (no/%) | 33 (66%) | 12 (86%) | 23 (64%) |
| Unilateral PU (no/%) | 8 (16%) | 1 (7%) | 6 (17%) |
| Panuveitis (no/%) | 9 (18%) | 1 (7%) | 7 (19%) |
| Retinal vasculitis (no/%) | 31 (62%) | 9 (64%) | 22 (61%) |
| Ocular attacks before IFX (total no/mean ± SD) | 285 (5.7 ± 5.7) | 61 (4.35 ± 3.29) | 224 (6.2 ± 6.3) |
| Previous treatment (no/%) | |||
| CS+AZA | 14 (28%) | 6 (43%) | 8 (22%) |
| CS+MTX | 6 (12%) | 2 (14%) | 4 (11%) |
| CS+CSA | 15 (30%) | 5 (36%) | 10 (28%) |
| CS+MTX+CSA | 11 (22%) | 1 (7%) | 10 (28%) |
| CS+AZA+CSA | 3 (6%) | 0 (0%) | 3 (8%) |
| CS+MTX+CSA+AZA | 1 (2%) | 0 (0%) | 1 (3%) |
| Ocular complications (no/%) | |||
| Cataract | 9 (18%) | 2 (14%) | 7 (19%) |
| Cystoid macular edema | 19 (38%) | 5 (36%) | 14 (39%) |
| Retinal detachments | 4 (8%) | 1 (7%) | 3 (8%) |
| Papillitis | 8 (16%) | 2 (14%) | 6 (17%) |
| Intra/subretinal hemorrhage | 5 (10%) | 1 (7%) | 4 (11%) |
| Intravitreal hemorrhage | 3 (6%) | 1 (7%) | 2 (5.5%) |
| Optic atrophy | 5 (10%) | 1 (7%) | 4 (11%) |
| Visual acuity (mean ± SD) | |||
| Right eye | 0.57 ± 0.31 | 0.6 ± 0.31 | 0.56 ± 0.32 |
| Left eye | 0.67 ± 0.28 | 0.65 ± 0.30 | 0.68 ± 0.27 |
Abbreviations: AZA, azathioprine; BD, Behçet’s disease; CS, corticosteroids; CSA, cyclosporine A; IFX, infliximab; MTX, methotrexate; PU, posterior uveitis; SD, standard deviation.